1. Scrip
  2. >>R&D

Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate

 
• By Ian Haydock

Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.  

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Setback For Avanir's Alzheimer's Agitation Candidate • Source: Shutterstock

Avanir Pharmaceuticals Inc.’s AVP-786 has failed in a Phase III North American study investigating its use in moderate-to-severe agitation in patients with Alzheimer’s dementia, prompting the California-based Otsuka Pharmaceutical Co. Ltd. subsidiary to reassess the continued development path for the molecule.

The second study (15-AVP-786-302 or TRIAD-2) was part of the company’s Phase III program investigating the therapy, which is a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.